Regeneron Pharmaceuticals Stock News

Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)

Regeneron Pharmaceuticals, Inc.'s shares have risen over 25% in recent months, reaching over $910 per share - a premium explained partly by share buybacks. The company's market cap is around $100 bill

Regeneron Pharmaceuticals (NASDAQ:REGN) shares fell over 3% in early Monday afternoon trading after it told investors that US net product sales of its franchise of Eylea totalled about $1.46 billion

The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.

Regeneron Pharmaceuticals said on Monday its franchise of eye drug Eylea recorded preliminary sales of $1.34 billion in the United States in the fourth quarter.

TARRYTOWN, N.Y., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2023 financial and operating resu

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Regeneron (REGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in

We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), Kanzhun Limited (BZ) and Stride (LRN) are well-poised to gain.

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle

The recent launch of Eylea HD should lead to stronger sales growth for Regeneron next year. The company's hematology-oncology business could get a boost with a possible drug approval.

Understandably, with the innovation sector printing a remarkable performance, all eyes have centered on Nasdaq-100 stocks. Indeed, on a year-to-date basis, the index shot up about 52%.

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.